Amyotrophic lateral sclerosis in Olmsted County, Minnesota, 1925 to 1998

Sorenson, Eric J.; Stalker, Andrew P.; Kurland, Leonard T.; Windebank, Anthony J.

doi:10.1212/wnl.59.2.280

Cited by 187 publications

(149 citation statements)

References 8 publications

Supporting

Mentioning

125

Contrasting

Order By: Relevance

“…We decided to take point 0 as time of diagnosis even this could mislead the comparison to other studies, setting our patients appearing to have worse status in less time. Nevertheless, there is no study with better outcome compared to our data at 1, 5 or 10 years of follow-up (Table 1) [14,15,22,73,80].…”

Section: Compared To Population-based Studiescontrasting

confidence: 72%

Point-Of-Care Stem Cell Therapy (POCST): Multisite transplantation of autologous bone marrow-derived mononuclear cells in 85 patients with Amyotrophic Lateral Sclerosis improves survival

Ruiz-Navarro¹,

Kobinia²

2017

JSRT

View full text Add to dashboard Cite

Section: Compared To Population-based Studiescontrasting

confidence: 72%

Point-Of-Care Stem Cell Therapy (POCST): Multisite transplantation of autologous bone marrow-derived mononuclear cells in 85 patients with Amyotrophic Lateral Sclerosis improves survival

Ruiz-Navarro¹,

Kobinia²

2017

JSRT

View full text Add to dashboard Cite

“…Also, although Rochester incidence rates appeared to increase after 65 years of age, they were not statistically different from the 55-to 64-year age stratum. Interestingly, a follow-up paper for this series by Sorenson et al 10 for cases diagnosed through 1998 found ALS incidence between 1990 and 1999 peaking at a perhaps slightly younger, 60-69 year age strata, with a mean age at symptom onset of 63 years.…”

Section: Als Disease Coursementioning

confidence: 74%

“…1° Some of the symptoms that can be treated palliatively include fatigue, dysphagia (i.e., difficulty swallowing), muscle spasticity, emotional lability, 3,4 sleeping problems, pain, depression, and sialorrhea (i.e., drooling). Death is usually the result of respiratory failure, 3 ' 4 and patient survival averages 1.5 to 2 years following diagnosis 0 -1 2 and 2.5 to 3 years 4 [10][11][12][13][14] following the appearance of the initial symptom.…”

Section: Clinical Features Of Alsmentioning

confidence: 99%

Case Series Investigation of Amyotrophic Lateral Sclerosis (ALS) Among Former Kelly Air Force Base Workers

Wackerman¹,

Shanklin²,

McGriff³

et al. 2005

PsycEXTRA Dataset

View full text Add to dashboard Cite

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

show abstract

“…The incidence of ALS is approximately one to two cases per 100,000 per year, with onset typically at around the age of sixty years, with survival of three to five years (Rowland, Shneider, 2001;Sorenson et al, 2002) ALS can occur in sporadic or familial form, which corresponds to only ten percent of cases. The possible involvement of free radicals in the etiology of ALS is suggested by the discovery that mutations in the gene encoding the antioxidant enzyme superoxide dismutase Cu / Zn (SOD1) are associated with familial ALS (Rosen et al, 1993).…”

Section: Amyotrophic Lateral Sclerosismentioning

confidence: 99%

Coenzyme Q10 and its effects in the treatment of neurodegenerative diseases

Santos¹,

Antunes

Santos

et al. 2009

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

According to clinical and pre-clinical studies, oxidative stress and its consequences may be the cause or, at least, a contributing factor, to a large number of neurodegenerative diseases. These diseases include common and debilitating disorders, characterized by progressive and irreversible loss of neurons in specific regions of the brain. The most common neurodegenerative diseases are Parkinson's disease, Huntington's disease, Alzheimer's disease and amyotrophic lateral sclerosis. Coenzyme Q10 (CoQ10) has been extensively studied since its discovery in 1957. It is a component of the electron transportation chain and participates in aerobic cellular respiration, generating energy in the form of adenosine triphosphate (ATP). The property of CoQ10 to act as an antioxidant or a pro-oxidant, suggests that it also plays an important role in the modulation of redox cellular status under physiological and pathological conditions, also performing a role in the ageing process. In several animal models of neurodegenerative diseases, CoQ10 has shown beneficial effects in reducing disease progression. However, further studies are needed to assess the outcome and effectiveness of CoQ10 before exposing patients to unnecessary health risks at significant costs.
De acordo com estudos clínicos e pré-clínicos, o estresse oxidativo e suas conseqüências podem ser a causa, ou, no mínimo, o fator que contribui para grande número de doenças degenerativas. Estas doenças incluem problemas comuns e debilitantes, caracterizados por perda progressiva e irreversível de neurônios em regiões específicas do cérebro. As doenças degenerativas mais comuns são doença de Parkinson, de Hutington, de Alzheimer e esclerose amiotrófica lateral. A Coenzima Q10 (CoQ10) tem sido intensamente estudada desde sua descoberta, em 1957. É um componente da cadeia de transporte eletrônico e participa da respiração aeróbica celular, gerando energia na forma de trifosfato de adenosina (ATP). A propriedade da CoQ10 de atuar como antioxidante ou pró-oxidante sugere papel importante na modulação do estado redox celular sob condições fisiológicas e patológicas, desempenhando, também, papel no processo de envelhecimento. Em vários modelos animais de doenças neurodegenerativas, a CoQ10 mostrou efeitos benéficos na redução do curso da doença. Entretanto, há necessidade de estudos adicionais para avaliar o efeito e a eficácia da CoQ10 antes de expor os pacientes a riscos de saúde desnecessários e de alto custo

show abstract

Amyotrophic lateral sclerosis in Olmsted County, Minnesota, 1925 to 1998

Cited by 187 publications

References 8 publications

Point-Of-Care Stem Cell Therapy (POCST): Multisite transplantation of autologous bone marrow-derived mononuclear cells in 85 patients with Amyotrophic Lateral Sclerosis improves survival

Point-Of-Care Stem Cell Therapy (POCST): Multisite transplantation of autologous bone marrow-derived mononuclear cells in 85 patients with Amyotrophic Lateral Sclerosis improves survival

Case Series Investigation of Amyotrophic Lateral Sclerosis (ALS) Among Former Kelly Air Force Base Workers

Coenzyme Q10 and its effects in the treatment of neurodegenerative diseases

Contact Info

Product

Resources

About